1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade%s Disease)-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease). This report provides information on the therapeutic development based on the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade%s Disease)-Pipeline Insights, 2014
Table of Contents
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Overview
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Pipeline Therapeutics
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics under Development by Companies
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Discontinued Products
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Dormant Products
- Companies Involved in Therapeutics Development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease), 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Assessment by Monotherapy Products
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Assessment by Combination Products
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Assessment by Route of Administration
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Assessment by Stage and Route of Administration
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Assessment by Molecule Type
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Assessment by Stage and Molecule Type
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics - Discontinued Products
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease), 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Assessment by Monotherapy Products
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Assessment by Combination Products
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Assessment by Route of Administration
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Assessment by Stage and Route of Administration
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Assessment by Molecule Type
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Mucopolysaccharidosis-Market Insights, Epidemiology and Market Forecast-2023

Mucopolysaccharidosis-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Mucopolysaccharidosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023

Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023

Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


Download Unlimited Documents from Trusted Public Sources

Endocrine Disease Statistics in the US

  • November 2016
    14 pages
  • Endocrine Disea...  

    Therapy  

  • United States  

View report >

Cardiovascular Disease Statistics in the Netherlands

  • November 2016
    103 pages
  • Cardiovascular ...  

  • Netherlands  

View report >

Cancer Statistics and Endocrine Disease Statistics in the US

  • November 2016
    124 pages
  • Cancer  

    Endocrine Disea...  

    Oncology  

  • United States  

View report >

Global Aids Statistics

2 months ago

Global Aids Statistics

2 months ago

Related Market Segments :

Endocrine Disease

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.